KRYS - Krystal Biotech: A Buy Ahead Of Their Pivotal DEB P3 Trial Readout

• KRYS, a clinical-stage gene therapy developer, has quadrupled its valuation since its IPO in 2017, and is currently 35% off from its 52 week high, a market cap of $1.25B.
• Within 3 years of its IPO, KRYS moves successfully from IND (Investigational New Drug) to a pivotal phase 3 trial of their lead candidate B-VEC for DEB (Dystrophic Epidermolysis Bullosa).
• The DEB p3 topline data is expected in Q4 2021. If successful, this readout will likely be a significant catalyst, as KRYS prepares for BLA filing and commercialization.
• In addition, KRYS has built a deep pipeline in rare skin diseases, lung and aesthetic indications, as well as in-house GMP manufacturing that can support its clinical & commercial needs.
• KRYS is a BUY for any who finds the risk/reward consideration favorable and has the right risk tolerance for R&D biotech stocks.

For further details see: